The committee recommends case-control studies examining the potential link between neurodevelopmental disorders and thimerosal-containing vaccines.
The committee recommends further analysis of neurodevelopmental disorders in cohorts of children who did not receive thimerosal-containing doses as part of a clinical trial of DTaP vaccine.
The committee recommends conducting epidemiological studies that compare the incidence and prevalence of neurodevelopmental disorders before and after the removal of thimerosal from vaccines.
The committee recommends an increased effort to identify the primary sources and levels of prenatal and postnatal background exposure to thimerosal (e.g., Rho (D) Immune Globulin) and other forms of mercury (e.g., maternal consumption of fish) in infants, children, and pregnant women.
The committee recommends research on how children, including those diagnosed with neurodevelopmental disorders, metabolize and excrete metals— particularly mercury.
The committee recommends continued research on theoretical modeling of ethylmercury exposures, including the incremental burden of thimerosal with background mercury exposure from other sources.
The committee recommends careful, rigorous, and scientific investigations of chelation when used in children with neurodevelopmental disorders, especially autism.
The committee recommends research to identify a safe, effective, and inexpensive alternative to thimerosal for countries that decide they need to switch from using thimerosal as a preservative.
The committee recommends research in appropriate animal models on the neurodevelopmental effects of ethylmercury.